STOCK TITAN

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Cybin Inc. (NYSE American:CYBN) announced its participation in the 2024 Milken Institute Future of Health Summit. CEO Doug Drysdale will speak on a panel titled 'The Next Frontier in Mental Health Research' on November 13, 2024, in Washington DC.

The discussion will focus on novel approaches to mental health treatments. Drysdale will share updates on Cybin's clinical advancements, including CYB003, their deuterated psilocin program for major depressive disorder entering Phase 3, and CYB004, their deuterated DMT program in Phase 2 for generalized anxiety disorder.

The panel will address mental illness, which affects one in eight people globally, exploring new therapeutic approaches and personalized treatment solutions.

Cybin Inc. (NYSE American:CYBN) ha annunciato la sua partecipazione al 2024 Milken Institute Future of Health Summit. Il CEO Doug Drysdale interverrà in un panel intitolato 'La Prossima Frontiera nella Ricerca sulla Salute Mentale' il 13 novembre 2024, a Washington DC.

La discussione si concentrerà su approcci innovativi ai trattamenti per la salute mentale. Drysdale condividerà aggiornamenti sui progressi clinici di Cybin, inclusi CYB003, il programma di psilocina deuterata per il disturbo depressivo maggiore che entra in Fase 3, e CYB004, il programma di DMT deuterato in Fase 2 per il disturbo d'ansia generalizzato.

Il panel affronterà la malattia mentale, che colpisce una persona su otto a livello globale, esplorando nuovi approcci terapeutici e soluzioni di trattamento personalizzate.

Cybin Inc. (NYSE American:CYBN) anunció su participación en el 2024 Milken Institute Future of Health Summit. El CEO Doug Drysdale hablará en un panel titulado 'La Próxima Frontera en la Investigación de la Salud Mental' el 13 de noviembre de 2024, en Washington DC.

La discusión se centrará en enfoques novedosos para los tratamientos de salud mental. Drysdale compartirá actualizaciones sobre los avances clínicos de Cybin, incluyendo CYB003, su programa de psilocina deuterada para el trastorno depresivo mayor que entra en la Fase 3, y CYB004, su programa de DMT deuterado en Fase 2 para el trastorno de ansiedad generalizada.

El panel abordará la enfermedad mental, que afecta a una de cada ocho personas a nivel mundial, explorando nuevos enfoques terapéuticos y soluciones de tratamiento personalizadas.

Cybin Inc. (NYSE American:CYBN)은 2024 Milken Institute Future of Health Summit에 참가한다고 발표했습니다. CEO Doug Drysdale가 2024년 11월 13일 워싱턴 DC에서 '정신 건강 연구의 다음 경계'라는 제목의 패널에서 연설할 예정입니다.

이번 논의는 정신 건강 치료의 혁신적인 접근 방식에 초점을 맞출 것입니다. Drysdale는 CYB003, 주요 우울 장애를 위한 3상에 들어가는 그들의 중수소화된 사이로신 프로그램과, CYB004, 일반화된 불안 장애에 대한 2상에 있는 중수소화된 DMT 프로그램에 대한 임상 발전 업데이트를 공유할 것입니다.

패널은 전 세계적으로 8명 중 1명이 영향을 받는 정신 질환에 대해 다루며, 새로운 치료 접근법과 개인화된 치료 솔루션을 탐구할 것입니다.

Cybin Inc. (NYSE American:CYBN) a annoncé sa participation au 2024 Milken Institute Future of Health Summit. Le PDG Doug Drysdale interviendra lors d'un panel intitulé 'La Prochaine Frontière de la Recherche en Santé Mentale' le 13 novembre 2024 à Washington DC.

La discussion portera sur des approches innovantes pour les traitements de la santé mentale. Drysdale partagera des mises à jour sur les avancées cliniques de Cybin, y compris CYB003, leur programme de psilocybine déuterée pour le trouble dépressif majeur entrant en Phase 3, et CYB004, leur programme de DMT déuteré en Phase 2 pour le trouble anxieux généralisé.

Le panel abordera la maladie mentale, qui touche une personne sur huit dans le monde, en explorant de nouvelles approches thérapeutiques et des solutions de traitement personnalisées.

Cybin Inc. (NYSE American:CYBN) gab bekannt, dass sie am 2024 Milken Institute Future of Health Summit teilnehmen wird. CEO Doug Drysdale wird am 13. November 2024 in Washington DC an einem Panel mit dem Titel 'Die nächste Grenze in der Forschung zur psychischen Gesundheit' teilnehmen.

Die Diskussion wird sich auf neuartige Ansätze zur Behandlung psychischer Gesundheit konzentrieren. Drysdale wird Updates zu Cybins klinischen Fortschritten geben, einschließlich CYB003, ihrem deuterierten Psilocin-Programm für die major depressive disorder, das in Phase 3 eintritt, und CYB004, ihrem deuterierten DMT-Programm in Phase 2 für die generalisierte Angststörung.

Das Panel wird psychische Erkrankungen ansprechen, die weltweit einen von acht Menschen betreffen, und neue therapeutische Ansätze sowie personalisierte Behandlungslösungen erkunden.

Positive
  • None.
Negative
  • None.

- CEO Doug Drysdale to speak on panel about novel approaches to mental health treatments on November 13, 2024 -

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 2024 Milken Institute Future of Health Summit on a panel entitled “The Next Frontier in Mental Health Research.”

“We share the Milken Institute’s inspiring commitment to accelerating medical research and improving health outcomes and are pleased to once again participate in this important event,” said Doug Drysdale, Chief Executive Officer of Cybin. “The Future of Health Summit is a unique opportunity for cross-discipline engagement around some of healthcare’s most challenging unmet needs. Cybin is proud to be a leader in innovative mental health research. As part of the larger panel discussion, we look forward to sharing our recent clinical advancements, including CYB003, our deuterated psilocin program for the adjunctive treatment of major depressive disorder, which is about to commence Phase 3, and CYB004, our deuterated DMT program in Phase 2 development for the treatment of generalized anxiety disorder.”

Milken Future of Health Summit: Partnering for Better Health

 

Panel title:

The Next Frontier in Mental Health Research

Date:

Wednesday, November 13, 2024

Time:

4:30 - 5:30 PM EST

Location:

Salamander, Washington DC, 1330 Maryland Avenue, SW

 

 

Description:

Mental illness is one of the most common health conditions—one in every eight people in the world lives with one. The staggering prevalence and impact of these illnesses has prompted worldwide research efforts to understand the causes and risk factors as well as to develop novel technologies and paradigms that more effectively diagnose and treat these illnesses. Today, therapeutic design efforts extend beyond those aimed at molecular and cellular mechanisms and include brain circuit organization and function. Such approaches offer the potential to link an individual’s symptom profile to personalized treatment for mental illness and open the door to new, innovative solutions for these conditions.

To access the live panel discussion, please click here. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page. For more information on the Milken Institute and the upcoming conference visit www.milkeninstitute.org.

About Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, about to enter Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated DMT program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to initiate its Phase 3 study of CYB003; proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of COVID-19 on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2024 and the Company’s annual information form for the year ended March 31, 2024, which are available under the Company's profile on www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor & Media Contact:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

irteam@cybin.com – or – media@cybin.com

Source: Cybin Inc.

FAQ

When is Cybin (CYBN) presenting at the 2024 Milken Institute Future of Health Summit?

Cybin's CEO Doug Drysdale will speak on November 13, 2024, from 4:30 - 5:30 PM EST at the Salamander in Washington DC.

What clinical programs will Cybin (CYBN) discuss at the Milken Institute Summit?

Cybin will discuss CYB003, their deuterated psilocin program entering Phase 3 for major depressive disorder, and CYB004, their Phase 2 deuterated DMT program for generalized anxiety disorder.

What is the topic of Cybin's (CYBN) panel at the 2024 Milken Health Summit?

Cybin will participate in a panel titled 'The Next Frontier in Mental Health Research,' discussing novel approaches to mental health treatments.

Where will the Cybin (CYBN) presentation take place at the Milken Institute Summit?

The presentation will take place at the Salamander, Washington DC, located at 1330 Maryland Avenue, SW.

Cybin Inc.

NYSE:CYBN

CYBN Rankings

CYBN Latest News

CYBN Stock Data

209.93M
18.64M
6.35%
36.61%
3.05%
Biotechnology
Healthcare
Link
United States of America
Toronto